Drawing for REBOVIR

USPTO serial 79023124

REBOVIR

Reviewed by CopyMark Law Group

Status 402
Filing date
Status date
Registration date
—
Examiner
CHENG, CHI TANG P
Law office
TTAB

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with REBOVIR?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
005Antivirals; pharmaceutical preparations for treating hepatitis; therapeutic preparations for treating hepatic disease, namely, antiviral nucleosides and Alanine Aminotransferase or Alanine Transaminase normalizations; preparations for normalizing or restoring metabolism; agents for immunity adjustment, namely, oral, transdermal, or injectable antiviral agents; biological preparations for medical purposes; agents affecting digestive organs, namely, agents for restoration of hepatic function; agents affecting the central nervous system, namely, agents for inhibiting virus reproduction; antibiotic preparations; and chemotherapy medicines, namely, pharmaceutical preparations for use in chemotherapyABANDONED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jun 17, 2016UNDNUNDELIVERABLE MAIL - NO ACTION TAKEN—
Jun 3, 2016DENANOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED—
Jun 2, 2016DETHDEATH OF INTERNATIONAL REGISTRATION—
Sep 25, 2008FINTFINAL DECISION TRANSACTION PROCESSED BY IB—
Sep 1, 2008FICSFINAL DISPOSITION NOTICE SENT TO IB—
Sep 1, 2008FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Sep 4, 2007MAB4ABANDONMENT NOTICE MAILED - INTER PARTES DECISION—
Sep 1, 2007ABN4ABANDONMENT - AFTER INTER PARTES DECISION—
Sep 1, 2007OP.SOPPOSITION SUSTAINED NO. 999999—
Jun 28, 2007LIMGLIMITATION OF GOODS RECEIVED FROM IB—
Jun 15, 2007RFNPREFUSAL PROCESSED BY IB—
May 25, 2007OP.IOPPOSITION INSTITUTED NO. 999999—
May 24, 2007OPNSOPPOSITION NOTICE (IB REFUSAL) SENT TO IB—
May 24, 2007OPNCOPPOSITION NOTICE (IB REFUSAL) CREATED—
Feb 26, 2007ETOFEXTENSION OF TIME TO OPPOSE RECEIVED—
Feb 20, 2007PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jan 31, 2007NPUBNOTICE OF PUBLICATION—
Dec 23, 2006PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Dec 23, 2006ALIEASSIGNED TO LIE—
Dec 7, 2006CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Nov 18, 2006TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Nov 17, 2006CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Nov 17, 2006TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jun 29, 2006RFNTREFUSAL PROCESSED BY IB—
Jun 9, 2006RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Jun 9, 2006RFRRREFUSAL PROCESSED BY MPU—
Jun 8, 2006RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Jun 7, 2006CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 2, 2006DOCKASSIGNED TO EXAMINER—
Jun 2, 2006NWAPNEW APPLICATION ENTERED—
Jun 1, 2006REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance